查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566964

Atorvastatin鈣市場：按形式、應用、分銷管道分類：2024-2033 年全球機會分析和產業預測

Atorvastatin Calcium Market By Form , By Application By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年Atorvastatin鈣市值為2.983億美元，預計2024年至2033年複合年成長率為5%，2033年達到4.878億美元。

Atorvastatin鈣是一種他汀類藥物，是預防心血管疾病的第一線藥物。它透過抑制 HMG-CoA 還原酶來降低血液膽固醇水平，HMG-CoA 還原酶在肝臟膽固醇合成中起著重要作用。該藥物可有效降低低密度脂蛋白（LDL）膽固醇，也可能有助於提高高密度脂蛋白（HDL）膽固醇。透過控制膽固醇水平，Atorvastatin鈣在預防心臟病、中風和其他嚴重心血管事件方面發揮重要作用。

全球Atorvastatin鈣市場的成長主要是由心血管疾病盛行率的驚人成長所推動的。根據世界心臟聯盟的數據，心血管疾病是全球第一大死因，超過其他原因。 2021 年，全球報告死亡人數約 2,050 萬人。此外，老年人口的快速增加也對市場成長做出了重大貢獻。這是由於老年人更容易患高膽固醇症和相關心血管疾病，導致對Atorvastatin等降膽固醇藥物的需求增加，從而推動市場成長。根據美國心臟協會2019年心臟病和中風統計更新，60至79歲族群心血管疾病的發生率據通報男性為77.2%，女性為78.2%。此外，久坐的生活方式和不健康的飲食模式導致人群膽固醇水平升高，從而增加了對Atorvastatin鈣的需求。此外，大眾對控制膽固醇水平對整體健康重要性的認知不斷提高，以及Atorvastatin學名藥學名藥的可用性正在推動全球市場的成長。聯合治療的日益普及是預計促進市場成長的主要趨勢。例如，Atorvastatin鈣和其他藥物（例如ezetimibe）的組合越來越普遍，以增強膽固醇管理的治療效果。然而，人們越來越擔心Atorvastatin鈣的潛在副作用，例如肌肉疼痛、肝損傷以及與其他藥物的相互作用，可能會限制其使用並阻礙市場成長。此外，替代他汀類藥物和其他降膽固醇藥物的供應也是全球市場的主要阻礙因素。相反，配方和給藥系統的創新正在提高Atorvastatin鈣的功效和便利性，預計將為預測期內的市場成長提供有利的機會。

全球Atorvastatin鈣市場按形式、應用、分銷管道和地區細分。按形式分類，市場分為錠劑和其他類型。依用途分為高膽固醇症、高血脂症等。依分銷通路分類，可分為醫院藥局、藥局/零售藥局、網路藥局。從區域來看，分析包括北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按格式分類，錠劑預計將在 2023 年錠劑2024 年至 2033 年佔據市場主導地位。

透過應用，高膽固醇症預計將成為未來幾年全球Atorvastatin鈣市場中利潤豐厚的部分。

從分銷管道來看，預計到 2033 年，線上藥局將成為主導細分市場。

按地區分類，就 2023 年收益而言，北美佔據最大的市場佔有率，預計將在預測期內主導Atorvastatin鈣市場。

可以使用此報告進行客製化（需要額外費用和時間表）

  • 國家、區域和全球各級的患者/流行病學資料
  • 根據客戶興趣加入公司簡介
  • 擴大公司簡介列表
  • 歷史市場資料
  • SWOT分析

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章Atorvastatin鈣市場：依形式

  • 市場概況
  • 錠劑
  • 其他

第5章 Atlastin 鈣市：依應用分類

  • 市場概況
  • 高膽固醇症
  • 高血脂症
  • 其他

第6章 阿曲他汀鈣市場：依通路分類

  • 市場概況
  • 醫院藥房
  • 藥局
  • 線上提供者

第7章阿曲他汀鈣市場：依地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國Atorvastatin鈣市場
    • 加拿大Atorvastatin鈣市場
    • 墨西哥Atorvastatin鈣市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 法國Atorvastatin鈣市場
    • 德國Atorvastatin鈣市場
    • 義大利Atorvastatin鈣市場
    • 西班牙Atorvastatin鈣市場
    • 英國Atorvastatin鈣市場
    • 其他歐洲Atorvastatin鈣市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 中國Atorvastatin鈣市場
    • 日本Atorvastatin鈣市場
    • 印度Atorvastatin鈣市場
    • 韓國Atorvastatin鈣市場
    • 澳洲Atorvastatin鈣市場
    • 其他亞太地區Atorvastatin鈣市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西阿托Atorvastatin鈣市場
    • 南非Atorvastatin鈣市場
    • 沙烏地Atorvastatin鈣市場
    • 其他拉丁美洲/中東/非洲Atorvastatin鈣市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第9章 公司簡介

  • Mylan Pharmaceuticals Inc.
  • Novartis AG
  • GlaxoSmithKline Plc
  • Amgen Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Industries Ltd
  • Merck And Co. Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca Plc
  • Pfizer Inc.
簡介目錄
Product Code: A324370

The atorvastatin calcium market was valued at $298.3 million in 2023, and is projected to reach $487.8 million by 2033, growing at a CAGR of 5% from 2024 to 2033.

Atorvastatin calcium is a statin medication, which acts as the first line of treatment for the prevention of cardiovascular diseases. It lowers the cholesterol levels in the blood by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver. This medication is effective in lowering low-density lipoprotein (LDL) cholesterol, and can also help to raise high-density lipoprotein (HDL) cholesterol. By managing cholesterol levels, atorvastatin calcium plays a crucial role in preventing heart attacks, strokes, and other serious cardiovascular events.

The growth of the global atorvastatin calcium market is majorly driven by alarming increase in prevalence of cardiovascular diseases. According to the World Heart Federation, cardiovascular diseases are the leading cause of death worldwide as compared to any other cause. Approximately 20.5 million deaths were reported in 2021 across the globe. In addition, surge in geriatric population significantly contributes toward the market growth. This is attributed to the fact that aged individuals are highly susceptible to hypercholesterolemia and related cardiovascular conditions, which, in turn, leads to higher demand for cholesterol-lowering medications like atorvastatin, thereby boosting the market growth. As per AHA 2019 Heart Disease and Stroke Statistical Update, the incidence of cardiovascular diseases was reported to be 77.2% in males and 78.2% in females, from ages 60-79 years. Moreover, rise in sedentary lifestyles and unhealthy eating patterns are leading to higher cholesterol levels among the population, thereby increasing the need for atorvastatin calcium. Furthermore, rise in public awareness of the importance of managing cholesterol levels for overall health and availability of generic versions of atorvastatin calcium boost the growth of the global market. Increase in popularity of combination therapies acts a key trend that is expected to augment the market growth. For instance, the use of atorvastatin calcium in combination with other drugs, such as ezetimibe, is becoming more common to enhance therapeutic outcomes for managing cholesterol levels. However, rise in concerns about potential side effects of atorvastatin calcium such as muscle pain, liver damage, and interactions with other medications can limit its use, which hampers the market growth. In addition, availability of alternative statins and other cholesterol-lowering drugs acts as key deterrent factor of the global market. On the contrary, innovations in drug formulation and delivery systems are enhancing the efficacy and convenience of atorvastatin calcium, which are expected to offer lucrative opportunities for the market growth during the forecast period.

The global atorvastatin calcium market is segmented into form, application, distribution channel, and region. On the basis of form, the market is categorized into tablets and others. By application, it is divided into hypercholesterolemia, hyperlipidemia, and others. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of form, the tablets segment dominated the market in 2023, and is is expected to dominate from 2024 to 2033.

By application, hypercholesterolemia is anticipated to be the lucrative segment in the global atorvastatin calcium market in the coming years.

Depending on distribution channel, online pharmacies is projected to emerge as the leading segment by 2033.

Region wise, North America held the largest market share in terms of revenue in 2023, and is expected to dominate the atorvastatin calcium market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global atorvastatin calcium market include Mylan Pharmaceuticals Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd, Merck and Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc., and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Form

  • Tablets
  • Others

By Application

  • Hypercholesterolemia
  • Hyperlipidemia
  • Others

By Distribution Channel

  • Hospital pharmacies
  • Drug store retail pharmacies
  • Online providers.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Mylan Pharmaceuticals Inc.
    • Novartis AG
    • GlaxoSmithKline plc
    • Amgen Inc.
    • Sanofi SA
    • Teva Pharmaceuticals Industries Ltd
    • Merck and Co. Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca Plc
    • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ATORVASTATIN CALCIUM MARKET, BY FORM

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Form
  • 4.2. Tablets
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Others
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: ATORVASTATIN CALCIUM MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Hypercholesterolemia
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Hyperlipidemia
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Others
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Drug Store Retail Pharmacies
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Providers.
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: ATORVASTATIN CALCIUM MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Form
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Atorvastatin Calcium Market
      • 7.2.6.1. Market Size and Forecast, By Form
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Atorvastatin Calcium Market
      • 7.2.7.1. Market Size and Forecast, By Form
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Atorvastatin Calcium Market
      • 7.2.8.1. Market Size and Forecast, By Form
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Form
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Atorvastatin Calcium Market
      • 7.3.6.1. Market Size and Forecast, By Form
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. Germany Atorvastatin Calcium Market
      • 7.3.7.1. Market Size and Forecast, By Form
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. Italy Atorvastatin Calcium Market
      • 7.3.8.1. Market Size and Forecast, By Form
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Spain Atorvastatin Calcium Market
      • 7.3.9.1. Market Size and Forecast, By Form
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. UK Atorvastatin Calcium Market
      • 7.3.10.1. Market Size and Forecast, By Form
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest of Europe Atorvastatin Calcium Market
      • 7.3.11.1. Market Size and Forecast, By Form
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Form
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Atorvastatin Calcium Market
      • 7.4.6.1. Market Size and Forecast, By Form
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. Japan Atorvastatin Calcium Market
      • 7.4.7.1. Market Size and Forecast, By Form
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. India Atorvastatin Calcium Market
      • 7.4.8.1. Market Size and Forecast, By Form
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. South Korea Atorvastatin Calcium Market
      • 7.4.9.1. Market Size and Forecast, By Form
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. Australia Atorvastatin Calcium Market
      • 7.4.10.1. Market Size and Forecast, By Form
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Atorvastatin Calcium Market
      • 7.4.11.1. Market Size and Forecast, By Form
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Form
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Atorvastatin Calcium Market
      • 7.5.6.1. Market Size and Forecast, By Form
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. South Africa Atorvastatin Calcium Market
      • 7.5.7.1. Market Size and Forecast, By Form
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. Saudi Arabia Atorvastatin Calcium Market
      • 7.5.8.1. Market Size and Forecast, By Form
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Atorvastatin Calcium Market
      • 7.5.9.1. Market Size and Forecast, By Form
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Mylan Pharmaceuticals Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Novartis AG
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. GlaxoSmithKline Plc
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Amgen Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Sanofi SA
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Teva Pharmaceuticals Industries Ltd
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Merck And Co. Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Bristol-Myers Squibb Company
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. AstraZeneca Plc
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Pfizer Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments